{"prompt": "['Novartis', 'Confidential', 'Page 59', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'Medication errors with randomized study treatment (study treatment errors) will be collected', 'on the DAR (dose administration record) eCRF. Refer to Section 5.5.5 for information', 'regarding interruptions of study treatment.', 'Misuse or abuse of randomized study treatment will be collected on the AE eCRF and', 'reported in the safety database irrespective of it being associated with an AE/SAE.', 'Table 7-1 Guidance for capturing the study treatment errors including misuse/abuse', 'Treatment error', 'Document in Dose', 'Document in AE', 'Complete SAE form', 'type', 'Administration (DAR)', 'eCRF', 'eCRF (Yes/No)', 'Study treatment', 'Yes', 'Only if associated with', 'Only if associated with an', 'error', 'an AE', 'SAE', 'Misuse/Abuse', 'Yes', 'Yes, even if not', 'Yes, even if not associated', 'associated with AE', 'with SAE', '7.5 Pregnancy reporting', 'To ensure patient safety, each pregnancy occurring after signing the informed consent must be', 'reported to Novartis within 24 hours of learning of its occurrence. The pregnancy should be', 'followed up to determine outcome, including spontaneous or voluntary termination, details of', 'the birth, and the presence or absence of any birth defects, congenital abnormalities, or', 'maternal and/or newborn complications.', 'Pregnancy must be recorded on the Pharmacovigilance Pregnancy Form and reported by the', 'investigator to the local Novartis Drug Safety and Epidemiology Department. Pregnancy', 'follow-up should be recorded on the same form and should include an assessment of the', 'possible relationship to the study treatment.', 'Any SAE experienced during the pregnancy and unrelated to the pregnancy must be reported', 'on a SAE form.', '8', 'Data review and database management', '8.1 Site monitoring', \"Before study initiation, at a site initiation visit or at an investigator's meeting, a Novartis\", 'representative will review the protocol and data capture requirements (i.e. eSource DDE or', 'eCRFs) with the investigators and their staff. During the study, Novartis employs several', \"methods of ensuring protocol and GCP compliance and the quality/integrity of the sites' data.\", 'The field monitor will visit the site to check the completeness of patient records, the accuracy', 'of data capture / data entry, the adherence to the protocol and to Good Clinical Practice, the', 'progress of enrollment, and to ensure that study treatment is being stored, dispensed, and', 'accounted for according to specifications. Key study personnel must be available to assist the', \"field monitor during these visits. Continuous remote monitoring of each site's data may be\", 'performed by a centralized Novartis CRA organization. Additionally, a central analytics', 'organization may analyze data & identify risks & trends for site operational parameters, and', 'provide reports to Novartis Clinical Teams to assist with trial oversight.']['Novartis', 'Confidential', 'Page 60', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'The investigator must maintain source documents for each patient in the study, consisting of', 'case and visit notes (hospital or clinic medical records) containing demographic and medical', 'information, laboratory data, electrocardiograms, and the results of any other tests or', 'assessments. All information on CRFs must be traceable to these source documents in the', \"patient's file. The investigator must also keep the original informed consent form signed by\", 'the patient (a signed copy is given to the patient).', 'The investigator must give the monitor access to all relevant source documents to confirm', 'their consistency with the CRF entries. Novartis monitoring standards require full verification', 'for the presence of informed consent, adherence to the inclusion/exclusion criteria,', 'documentation of SAEs, and of data that will be used for all primary variables. Additional', 'checks of the consistency of the source data with the CRFs are performed according to the', 'study-specific monitoring plan. No information in source documents about the identity of the', 'patients will be disclosed.', '8.2 Data collection', 'Designated investigator site staff will not be given access to the system until they have been', 'trained. All data will be handled in alignment with current legislation on data protection.', \"Study documents including patients' files will be stored secure at clinical site. Only a principal\", \"investigator and named study personal will have access to patients' files. Data transferred to\", 'Novartis systems are coded and protected from unauthorized break-in. Identified site users', 'will receive an individual login and password or biometric fingerprint identification.', 'Passwords used to access Novartis (and its vendors) systems need to be of appropriate', 'strength and need to be changed regularly. Novartis personal computers require two factor', 'authorizations. Additionally access to all data server rooms used to store hardware and', 'software for this trial is restricted only to those staff with appropriate access rights. Access to', 'systems which are no longer in use will be removed; also access of users no longer involved', 'in the conduct of the study will be removed. On the contrary, new staff will be carefully', 'trained before being allowed to access confidential or personal files (on-site training,', 'investigator meeting and vendor specific trainings). Staff must ensure that unauthorized', 'persons are unable to view or process personal or sensitive information in a paper form or', 'displayed electronically. Personal data are stored centrally only in pseudonymous form.', 'Electronic transfer of data is always encrypted and takes place via secure on-line channels', 'providing the highest level of security. Spirometers and any other devices capturing clinical or', 'personal data must not contain unauthorized, unlicensed or personally licensed software. All', 'software must be authorized and procured through Novartis or its vendors. Electronic devices', 'are secured by up-to-date anti-virus, anti-spyware and personal firewall. Only known', 'machines are allowed to remotely access centrally held personal or sensitive data. In addition', 'Novartis as well as clinical site regulate use of information and communication technologies', 'by their staff in order to avoid unauthorized break-in to the network.', '8.3 Database management and quality control', 'Novartis staff [or CRO working on behalf of Novartis] review the data entered into the CRFs', 'by investigational staff for completeness and accuracy and instruct the site personnel to make', 'any required corrections or additions. Queries are sent to the investigational site using an']\n\n###\n\n", "completion": "END"}